The Value of Serum Albumin for Prediction of In-Hospital Complications in Patients with Acute Myocardial Infarction
| International Journal of Medical Science |
| © 2023 by SSRG - IJMS Journal |
| Volume 10 Issue 5 |
| Year of Publication : 2023 |
| Authors : Majd khawashki, Akram jahjaj |
10.14445/23939117/IJMS-V10I5P110
How to Cite?
Majd khawashki, Akram jahjaj, "The Value of Serum Albumin for Prediction of In-Hospital Complications in Patients with Acute Myocardial Infarction," SSRG International Journal of Medical Science, vol. 10, no. 5, pp. 65-73, 2023. Crossref, https://doi.org/10.14445/23939117/IJMS-V10I5P110
Abstract:
Introduction: Despite significant advancements in medical care, ischemic heart disease, notably acute myocardial infarction, remains the leading cause of morbidity and mortality worldwide; given the complexity of the atherosclerosis process, the severity of the associated pathologies, it is crucial to explore new prognostic factors that may have an impact on the course of this disease. Previous studies have shown that serum albumin is a powerful prognostic factor in various other conditions. Objective: to study the relationship between low serum albumin and the occurrence of complications in patients with acute myocardial infarction during hospitalization. Methods: the study included 93 patients with acute myocardial infarction with or without ST-segment elevation who attended Tishreen University Hospital in Lattakia, Syria, during the period from June 2022 to June 2023, and was divided into two groups: hypoalbuminemia group 36 patients (albumin <3.5 g/dl) and normal albumin group 57 (albumin ≥ 3.5 g/dl). Results: complications were more prevalent in the hypoalbuminemia group, 61.1%, compared to 26.3% in the normal albumin group, with a statistically significant difference (P-value: 0.001). Specifically, there was a higher incidence of mortality (P-value:0.03), acute heart failure (P-value:0.002) and cardiogenic shock (P-value:0.003) in the hypoalbuminemia group. Conclusions: Low serum albumin levels in patients with acute myocardial infarction (STEMI or NSTEMI) have significant predictive value for complications during hospitalization, particularly death, acute heart failure, and cardiogenic shock.
Keywords:
Acute myocardial infarction, Complications, Hypoalbuminemia, Mortality, STEMI.
References:
[1] P. Gosling, “Albumin and the Critically Ill,” Care of Critically Ill, Critical Care Publication, vol. 11, pp. 57-61, 1995.
[Google Scholar]
[2] Theodore Peters Jr, All about Albumin. Biochemistry, Genetics and Medical Applications, Academic Press, San Diego 1996.
[Google Scholar] [Publisher Link]
[3] A. Fleck et al., “Increased Vascular Permeability: A Major Cause of Hypoalbuminaemia in Disease and Injury,” The Lancet, vol. 325, no. 8432, pp. 781-78, 1985.
[CrossRef] [Google Scholar] [Publisher Link]
[4] Olivia Alejandra Aguayo-Becerra et al., “Serum Albumin Level as a Risk Factor for Mortality in Burn Patients,” Clinics (Sao Paulo), vol. 68, no. 7, 2013.
[CrossRef] [Google Scholar] [Publisher Link]
[5] erena Gounden, Rishik Vashisht, and Ishwarlal Jialal, “Hypoalbuminemia,” StatPearls, 2019.
[Google Scholar] [Publisher Link]
[6] C. Haller, “Hypoalbuminemia in Renal Failure: Pathogenesis and Therapeutic Considerations,” Kidney Blood Pressure Research, vol. 28, no. 5-6, pp. 307–310, 2006.
[CrossRef] [Google Scholar] [Publisher Link]
[7] Angelo Gatta, Alberto Verardo, and Massimo Bolognesi,“Hypoalbuminemia,” Internal and Emergency Medicine, vol. 7, no. 3, pp. 209-212, 2012.
[CrossRef] [Google Scholar] [Publisher Link]
[8] Rebecca J. Traylor, and Ronald G. Pearl, “Crystalloid Versus Colloid Versus Colloid: All Colloids are not Created Equal,” Anesthesia & Analgesia, vol. 83, no. 5, pp. 1-6, 2014.
[CrossRef] [Google Scholar] [Publisher Link]
[9] Ulrich Kragh-Hansen, “Human Serum Albumin: A Multifunctional Protein,” Albumin in Medicine: Pathological and Clinical Applications, pp. 1-24, 2016.
[CrossRef] [Google Scholar] [Publisher Link]
[10] Robert H. Demling, Effect of Plasma and Interstitial Protein Content on Tissue Oedema Formation, Current Studies in Hematology and Blood Transfusion, vol. 53, pp. 36-52, 1986.
[CrossRef] [Google Scholar] [Publisher Link]
[11] M.A Kaufmann et al., “Nitric Oxide Dose–Response Study in the Isolated Perfused Rat Kidney after Inhibition of Endothelium-Derived Relaxing Factor Synthesis: The Role of Serum Albumin,” Journal of Pharmacology and Experimental Therapeutics, vol. 273, no. 2, pp. 855-862, 1995.
[Google Scholar] [Publisher Link]
[12] M.E. Holt, M.E. Ryall, and A.K. Campbell, “Albumin Inhibits Human Polymorphonuclear Leucocyte Luminol-Dependent Chemi Luminescence: Evidence for Oxygen Radical Scavenging,” British Journal of Experimental Pathology, vol. 65, no. 2, pp. 231–241, 1984.
[Google Scholar] [Publisher Link]
[13] Robert N. Foleyet et al., “Hypoalbuminemia, Cardiac Morbidity, and Mortality in End-Stage Renal Disease,” Journal of the American Society of Nephrology, vol. 7, no. 5, pp. 728–736, 1996.
[CrossRef] [Google Scholar] [Publisher Link]
[14] Wenhua Peng et al., “Prediction of All-Cause Mortality with Hypoalbuminemia in Patients with Heart Failure: A Meta-Analysis,” Biomarkers, vol. 24, no. 7, pp. 631–637, 2019.
[CrossRef] [Google Scholar] [Publisher Link]
[15] Digant Gupta, and Christopher G. Lis, “Pretreatment Serum Albumin as a Predictor of Cancer Survival: A Systematic Review of the Epidemiological Literature,” Nutrition Journal, vol. 9, no. 1, pp. 1-16, 2010.
[CrossRef] [Google Scholar] [Publisher Link]
[16] Gulam Rabbani, and Saeyoung Nate Ahn, “Review: Roles of Human Serum Albumin in Prediction, Diagnoses and Treatment of Covid-19,” International Journal of Biological Macromolecules, vol. 193, pp. 948–955, 2021.
[CrossRef] [Google Scholar] [Publisher Link]
[17] Peter Libby, “Molecular Bases of the Acute Coronary Syndromes,” Circulation, vol. 91, no. 11, 1995.
[CrossRef] [Google Scholar] [Publisher Link]
[18] Cem Gabay, and Irving Kushner, “Acute-Phase Proteins and other Systemic Responses to Inflammation,” The New England Journal of Medicine, vol. 340, pp. 448-455, 1999.
[CrossRef] [Google Scholar] [Publisher Link]
[19] Kristian Thygesen et al., “Third Universal Definition of Myocardial Infarction,” European Heart Journal, vol. 33, no. 20, pp. 2551– 2567, 2012.
[CrossRef] [Google Scholar] [Publisher Link]
[20] John J.V. McMurray et al., “ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in Collaboration with the Heart Failure Association (HFA) of the ESC,” European Heart Journal, vol. 33, no. 14, pp. 1787–1847, 2012.
[CrossRef] [Google Scholar] [Publisher Link]
[21] Piotr Ponikowski et al., “2016 ESC Guidelines for the Diagnosis and Treatment of acute and Chronic Heart Failure,” European Journal of Heart Failure, vol. 18, no. 8, pp. 891-975, 2016.
[CrossRef] [Google Scholar] [Publisher Link]
[22] Anggoro Budi Hartopo, Putrika Prastuti Ratna Gharini, and Budi Yuli Setianto, “Low Serum Albumin Levels and In-Hospital Adverse Outcomes in Acute Coronary Syndrome,” International Heart Journal, vol. 51, no. 4, pp. 221-226, 2010.
[CrossRef] [Google Scholar] [Publisher Link]
[23] Peter Libby, Paul M. Ridker, and Göran K. Hansson, “Progress and challenges in Translating the Biology of Atherosclerosis,” Nature, vol. 473, pp. 317- 325, 2011.
[CrossRef] [Google Scholar] [Publisher Link]
[24] Jean Davignon, and Peter Ganz, “Role of Endothelial Dysfunction in Atherosclerosis,” Circulation, vol. 109, no. 3, pp. 27-32, 2004.
[CrossRef] [Google Scholar] [Publisher Link]
[25] Maura Brioschi et al., “S-Thiolation Targets Albumin in Heart Failure,” Antioxidants, vol. 9, no. 8, pp. 1-12, 2020.
[CrossRef] [Google Scholar] [Publisher Link]
[26] John F. Keaney, et al., “NO Forms an Adduct with Serum Albumin that has Endothelium-Derived Relaxing Factor-Like Properties,” The Journal of Clinical Investigation, vol. 91, no. 4, pp. 1582-1589, 1993.
[CrossRef] [Google Scholar] [Publisher Link]
[27] Undurti N. Das, Molecular Basis of Health and Disease, Springer, 2011.
[Google Scholar] [Publisher Link]
[28] Das UN, “Albumin and Lipid Enriched Albumin for the Critically Ill,” The Journal of the Association of Physicians of India, vol. 57, pp. 53–63, 2009.
[Google Scholar] [Publisher Link]
[29] D.P. Mikhailidis, A.M. Mikhailidis, and P. Dandona, “Effect of Human Plasma Proteins on Stabilisation of Platelet Anti-Aggregatory Activity of Prostacyclin,” Annals of Clinical Biochemistry, vol. 19, no. 4, pp. 241–244, 1982.
[CrossRef] [Google Scholar] [Publisher Link]
[30] J.P. Nicholson, M.R. Wolmarans, and G.R. Park, “The Role of Albumin in Critical Illness,” British Journal of Anaesthesia, vol. 85, no. 4, pp. 599-610, 2000.
[CrossRef] [Google Scholar] [Publisher Link]
[31] David G. Levitt, and Michael D. Levitt, “Human Serum Albumin Homeostasis: A New Look at the Roles of Synthesis, Catabolism, Renal and Gastrointestinal Excretion, and the Clinical Value of Serum Albumin Measurements,” International Journal of General Medicine, vol. 9, pp. 229-255, 2016.
[CrossRef] [Google Scholar] [Publisher Link]
[32] Gabriella Fanali et al., “Human Serum Albumin: From Bench to Bedside,” Molecular Aspects of Medicine, vol. 33, no. 3, pp. 209– 290, 2012.
[CrossRef] [Google Scholar] [Publisher Link]
[33] Koichi Kaikita, and Kenichi Tsujita, “Hypoalbuminemia and Inflammation as Prognostic Markers in Patients Undergoing Percutaneous Coronary Intervention,” Circulation Journal, vol. 81, no. 9, pp. 1268-1269, 2017.
[CrossRef] [Google Scholar] [Publisher Link]
[34] Mitchell Padkins et al., “Association between Albumin Level and Mortality among Cardiac Intensive Care Unit Patients,” Journal of Intensive Care Medicine, vol. 36, no. 12, pp. 1475–1482, 2021.
[CrossRef] [Google Scholar] [Publisher Link]
[35] Lingjun Zhu, Miaomiao Chen, and Xiaoping Lin, “Serum Albumin Level for Prediction of All-Cause Mortality in Acute Coronary Syndrome Patients: A Meta-Analysis,” Bioscience Reports, vol. 40, no. 1, pp. 1–8, 2020.
[CrossRef] [Google Scholar] [Publisher Link]
[36] Stephane Arques, “Human Serum Albumin in Cardiovascular Diseases,” European Journal of Internal Medicine, vol. 52, pp. 8–12, 2018.
[CrossRef] [Google Scholar] [Publisher Link]
[37] Justin L. Grodin et al., “Clinical Implications of Serum Albumin Levels in Acute Heart Failure: Insights from DOSE-AHF and ROSEAHF,” Journal of Cardiac Failure, vol. 22, no. 11, pp. 884–890, 2016.
[CrossRef] [Google Scholar] [Publisher Link]
[38] Hector Gonzalez-Pacheco et al., “Prognostic Implications of Serum Albumin Levels in Patients with Acute Coronary Syndromes,” The American Journal of Cardiology, vol. 119, no. 7, pp. 951-958, 2017.
[CrossRef] [Google Scholar] [Publisher Link]
[39] Nehal Rachit Shah, and Francis Dumler, “Hypoalbuminaemia—A Marker of Cardiovascular Disease in Patients with Chronic Kidney Disease Stages II-IV,” International Journal of Medical Sciences, vol. 5, no. 7, pp. 366-370, 2008.
[CrossRef] [Google Scholar] [Publisher Link]
[40] Shih-Chieh Chien et al., “Critical Appraisal of the Role of Serum Albumin in Cardiovascular Disease,” Biomarker Research, vol. 5, no. 31, pp. 1-9, 2017.
[CrossRef] [Google Scholar] [Publisher Link]
[41] Pierpaolo De Feo, Margaret Gan Gaisano, and Morey W. Haymond, “Differential Effects of Insulin Deficiency on Albumin and Fibrinogen Synthesis in Humans,” The Journal of Clinical Investigation, vol. 88, no. 3, pp. 833-840, 1991.
[CrossRef] [Google Scholar] [Publisher Link]
[42] Aaron R. Folsom et al., “Low serum albumin. Association with Diabetes Mellitus and Other Cardiovascular Risk Factors but Not with Prevalent Cardiovascular Disease or Carotid Artery Intima-Media Thickness. The Atherosclerosis Risk in Communities (ARIC) Study Investigators,” Annals of Epidemiology, vol. 5, no. 3, pp. 186-191, 1995.
[CrossRef] [Google Scholar] [Publisher Link]
[43] Cem Gabay, and Irving Kushner, “Acute-Phase Proteins and Other Systemic Responses to Inflammation,” New England Journal of Medicine, vol. 340, no. 6, pp. 448-454, 1999.
[CrossRef] [Google Scholar] [Publisher Link]
[44] Keith A.A Fox, “Prediction of Risk of Death and Myocardial Infarction in the Six Months after Presentation with Acute Coronary Syndrome: Prospective Multinational Observational Study (Grace),” BMJ, vol. 333, pp. 1091-1094, 2006.
[CrossRef] [Google Scholar] [Publisher Link]
[45] Thomas Killip III, and John T. Kimball, “Treatment of Myocardial Infarction in a Coronary Care Unit. A Two Year Experience with 250 Patients,” The American Journal of Cardiology, vol. 20, no. 4, pp. 457-464, 1967.
[CrossRef] [Google Scholar] [Publisher Link]